We are a clinical-stage biopharmaceutical company committed to the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. We are currently focused on providing a novel once-daily eye drop treatment option, Nyxol®, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of our strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes, and to seek strategic partners for global commercialization.
